Previous close | 25.13 |
Open | 25.40 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's range | 25.22 - 25.52 |
52-week range | 20.12 - 32.94 |
Volume | |
Avg. volume | 156,786 |
Market cap | N/A |
Beta (5Y monthly) | 1.01 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | 24 Jul 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Valmet's Half Year Financial Review January 1 – June 30, 2024: Orders received remained at the previous year's level and amounted close to EUR 1.3 billion and Comparable EBITA decreased to EUR 141 million in the second quarter
Velvet CARE has decided to invest in a third Valmet Advantage DCT tissue line for its mill in Osada Klucze, Poland. The order includes an extensive automation package, a control valve package, and Industrial Internet solutions. The target is to meet consumers' increasing demand for high-quality tissue products with low environmental impact.
According to Valmet Oyj's Annual General Meeting's decision, Valmet's Nomination Board consists of the representatives of Valmet's four largest shareholders as of July 1, and the Chair of the Board of Directors as an expert member. Should a shareholder not wish to exercise his/her nomination right, the right shall be transferred to the next largest shareholder who otherwise would not be entitled to nominate a member.